Company intelligence / Profile preview

New Horizon Evergreen Investment

Beijing, China

Ownership: Private
Development stage: Other

Overview

New Horizon Capital is a leading China-focused private equity firm that manages the New Horizon Evergreen Investment vehicle. Founded in 2005, the firm specializes in growth-stage investments across several key sectors, including healthcare, advanced manufacturing, consumer products, and alternative energy. New Horizon Capital is recognized for its deep expertise in the Chinese market and its ability to support companies through strategic guidance and capital. Its healthcare portfolio has included significant investments in biotechnology and pharmaceutical companies such as Cathay Industrial Biotech and Alexza Pharmaceuticals. The firm operates offices in Hong Kong and Beijing, maintaining a strong presence in the Asian investment landscape.

Industry: Investors

Beyond the preview

Go deeper on New Horizon Evergreen Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Horizon Evergreen Investment.

Explore the full profile